Background: More than half of the families with breast and/or ovarian cancer (BC/OC) have no BRCA1 or BRCA2 mutation, moreover the broad lifetime risks reported within families with a BRCA1/2 mutation suggest other genes are also responsible.
INTRODUCTION
More than 50% of the families with BC and OC do not have mutations in the BRCA1 and BRCA2 genes [1] [2] [3] [4] . So far, linkage analyses have failed in identifying new high penetrant genetic risk-factors responsible for the familial aggregation of those malignancies. It is hypothesized that the genetic basis in the remaining cases is highly heterogeneous [3] [4] [5] [6] and that genes involved are low penetrant such as the CHEK2*1100delC variant [7, 8] . In addition, within families with a mutation in BRCA1 or BRCA2, several lines of evidence suggest that additional genetic risk-factors/modifiers are present. For example, no current explanation exists for the fact that: i) in families with the same BRCA1 or BRCA2 mutation, some individuals develop BC, some OC, and others develop either both cancers or none; and ii) for the broad life-time risks for breast and OC reported among carriers of the same BRCA1 or BRCA2 mutation (Stanford Comprehensive Cancer Center statistics; http://cancer.stanford.edu/). Recent evidence for genetic modifiers have been provided by Smith and colleagues, who showed that women who tested negative for the familial BRCA1/BRCA2 mutation do have an increased risk for BC compared to the general population [9] .
*Address correspondence to this author at the Department of Clinical Genetics, Maastricht University Medical Center, P.O. box 5800, 6202 AZ Maastricht, The Netherlands; Tel: +31 -43 -3875855; Fax: +31 -43 -3875800; E-mail: Encarna. Gomezgarcia@gen.unimaas.nl Despite the fact that the DNA-repair action of BRCA1 and BRCA2 proteins is ubiquitous across the human tissues, it is noteworthy that their inactivation leads predominantly to cancer of the breast and ovaries. In these tissues, cell homeostasis is mainly controlled by steroid hormones (estrogen and progesterone) and their respective receptors. Furthermore, it has recently been shown that a progesterone antagonist prevents BRCA1-mediated breast tumorigenesis in a mousemodel [10] . It is therefore plausible that genetic variants modifying the action of steroid hormone receptors might modify, alone or in combination with other risk-factors, the risk for BC and OC.
The progesterone receptor (PR) has two isoforms, PRA and PRB, which mediate all major responses to progesterone such as proliferation in the breast (mediated mainly through PRB [11] ), and apoptosis in the ovarian epithelium (through PRA [12] ).
Two functional PR gene polymorphisms (PROGINS and +331G/A) have been identified. PROGINS is a haplotype of three genetic variations in complete linkage disequilibrium: G3432T (Val660Leu substitution), C3764T (silent, His770His), and a HS-1/PV Alu insertion in intron G. PROGINS has a frequency of 0.12-0.16 among Caucasians [13] [14] [15] and reduces the activity of both PRA and PRB [16] . In case of the +331G/A promoter polymorphism [13] , the rare allele +331A (with a frequency of 0.06-0.08 among Caucasians) increases the relative PRB/PRA expression compared to +331G. Both polymorphisms have been shown to modify the risk for breast [2, [17] [18] [19] and OC [14, 15, 17, 20, 21] in several case-control studies. However these associations were not confirmed by other studies [13, 17, [22] [23] [24] [25] [26] . The role of these PR variants in the pathogenesis of familial BC and OC is largely unknown.
The aim of our study is to evaluate the role of +331A and PROGINS as risk-factors for familial BC and OC, alone or in combination with sequence variants in the BRCA1 and BRCA2 genes or with CHEK2*1100delC. We studied the prevalence, the genotype-tumor phenotype associations and the gene-gene interactions in a population of randomly selected probands who were tested for BRCA1 and BRCA2 mutations because of a family history of BC and OC.
MATERIALS AND METHODOLOGY

Study Population
Three-hundreds and eighteen (318) probands (men and women) were randomly selected from a DNA bank of pa- 
Genetic Analysis
BRCA1 and BRCA2: DNA extraction and genetic analysis of BRCA1 and BRCA2 mutations have been already described [27] . Mutation screening included the whole coding sequence plus splice junctions of the BRCA1 and BRCA2 genes. The term 'sequence variants' in the present study refers to both genetic unclassified variants (UVs) and truncating mutations ( Table 1) . In addition, a number of rare polymorphisms previously classified as UVs found amongst the probands are also listed in Table 1 . Results of BRCA1 and BRCA2 screening were revealed only after the genotyping for the other three genetic markers was completed.
Progesterone receptor (PR) polymorphisms: PROGINS
(A1/A2; Reference SNP Cluster Report: rs1042838 1 and rs1042839 2 and NCBI Z49816 3 ) and +331G/A (rs10895068) detection was performed by restriction fragment length polymorphism analysis [15] . Analyses were performed twice to reduce the risk of miss-genotyping. With respect to the PROGINS polymorphism, only the V660L substitution in exon 4 (G3432T) was genotyped and used to assess the presence or the absence of the PROGINS allele. A1 refers to the most common allele, A2 to PROGINS. CHEK2*1100delC: was detected by PCR, followed by DNA sequence analysis. Exon 10 of the CHEK2 gene was amplified using specific primers: 5' GCAAGTTCAACAT-TATTCCCTTTT (forward) and 5' ATCACCTCCTAC-CAGCCTGTGC (reverse). The PCR reaction was performed using the Taq polymerase (Invitrogen, Life Technologies, Inc., Carlsbad, CA) as recommended by the manufacturer with 33 ng of genomic DNA. PCR conditions consisted of 6 touch-down cycles (annealing temperature from 64°C to 60.5°C) and 72°C/45 sec of elongation, followed by 30 extra cycles (94°C/30 sec, 60.5°C/30 sec and 72°C/45 sec). The PCR products (245bp) were sequenced using the BigDye Terminator kit 1.1 (Applied Biosystems, Warrington Cheshire, UK) and the ABI3100 sequencer.
Statistical Analysis
Genetic clustering: expected numbers of probands in which more than one genetic variant co-occurred were 1 rs1042838 refers to the G3432T in exon 4, Val660Leu. Nucleotide position is based on cDNA counting, NCBI X51730. 2 rs1042839 refers to the C3764T in exon 5 His770His. 3 NCBI Z49816 corresponds the HS-1/PV Alu insertion in intron G. NCBI Reference SNP Cluster Report: http://www.ncbi.nlm.nih.gov/entrez estimated based on the frequency of each variant in the study population. Expected number and observed numbers were compared using a log-linear model.
Gene-phenotype correlations:
were assessed by Fisher's exact test in the CF-group.
RESULTS
I. Genotype Distribution
The present study includes 318 randomly selected probands tested for BRCA1 and BRCA2 mutations because of a family history of breast or OC. Table 2 shows the allele frequencies of each of the genetic parameters investigated. The two PR polymorphisms and the CHEK2*1100delC variant were in Hardy-Weinberg equilibrium (not shown). Two-hundred-seventy-eight (278) individuals were successfully screened for all the genetic factors. Fig. 1 displays their genotypic distribution. None of the patients who carried a genetic variant in the BRCA1 or BRCA2 gene, carried also the CHEK2*1100delC variant. On the contrary, PROGINS and +331A were present both among BRCA1 and BRCA2 sequence variant carriers as in the BRCA1 and BRCA2 wildtype group Fig. 1 . In particular, the co-occurrence of homozygous +331A/A and BRCA2 mutations was significantly higher than expected by chance alone (observed number = 1, expected number = 0.078, ratio (obs/exp) = 12.8, 95% CI=1.8-91.0; log-linear model). The only other case with a homozygous +331A/A observed in this series did show a rare polymorphism in the BRCA2 gene: Lys2950Asn.
II. Clinical Characteristics
Clinical information was available from 220 patients (i.e. CF group). The majority of the CF-group (187/220; 6 men and 181 women) had been diagnosed with BC. From these, 21 women had primary BC twice (ipsi-or contralateral) and 24 were diagnosed with epithelial OC. Three of these 24 women also developed BC. Twelve women had not been diagnosed with any cancer. The inclusion criteria for BRCA1 and BRCA2 genetic diagnosis (indication for DNA analysis) and additional clinical features are also described in Table 3 .
The 220 probands belonged to 214 independent families including 3949 first and second-degree family members [2087 (52.8%) female, 1721 (43.6%) male and 148 (3.6%) of unknown gender]. Over 95% of the families (204/214) presented at least one case of BC (maximum 6 cases; average age at diagnose: 51.1±9.9) and about half of the families (109/214) had three or more relatives with BC (including the proband). A total of 564 relatives with BC were recorded. Twenty-nine families (0.7%) presented at least one patient with two primary breast cancers.
About one quarter of the families (51/214, 23.8%) had at least one case of OC and 19 families (9.0%) had two or more cases of OC (maximum 4 cases; average age at diagnose: 53.7±13.6). A total of 78 relatives having OC were recorded. Cancers at sites other than breast and ovaries were seen in half of the families: colon cancer (70 cases), lung cancer (n=27), prostate cancer (n=19), gastric cancer (n=15), skin cancer (n=14), brain tumors (n=12), pancreatic cancer (n=11), ORL cancer (n=11), cervical cancer (n=5), leukemia (n=5), bladder cancer (n=4), other cancers (n=47).
III. Genotype Phenotype Correlations (Table 4)
III-a. PROGINS PR Polymorphism
The PROGINS allele (A1/A2 or A2/A2) was significantly more frequent among male compared to female probands, Fig. (1) . Genotype distribution and co-occurrence of more than one rare genetic variant in the population. Genotype distribution is represented in I) the whole population (circle at the bottom); II) carriers of a sequence variant in the BRCA1 gene (above middle); III) carriers of a sequence variant in the BRCA2 gene (left), and IV) BRCA1 and BRCA2 wild-type carriers (circle at the right). Unless specified in the footnotes, probands were heterozygous for the genetic variant under consideration. a: Five of 51 probands were A2/A2 and 46 were A1/A2. b: Sixteen of the 17 probands were +331G/A and one was +331A/A. c: Two of the three probands were +331G/A and one was +331A/A. a breast cancer patients include 6 men. b the average age of breast cancer in man onset was 59.0 ± 6.6. c other sites of cancer onset were colon (n=2), brain (n=3), melanoma (n=4), pancreas (n=1), (mesothelioma in peritoneum, n=1) and one ORL cancer. All women presenting cancer at sites other than breast or ovary were also diagnosed with breast (n=11) or ovarian (n=1) cancer. d presymptomatic indicates that the variant in BRCA1 or BRCA2 was already known in the family.
both in the whole group (n=220; p=0.047) and among patients diagnosed with BC (n=167; p=0.04). Further, patients carrying the PROGINS allele did not differ significantly with respect to any of the other investigated clinical or histological features.
III-b. +331G/A PR Polymorphism
Patients carrying the +331A allele were diagnosed more frequently with two primary BC and with OC than noncarriers. These differences were of borderline significance (p=0.09 and 0.07, respectively; Table 4 ).
III-c. CHEK2*1100delC Variant
All CHEK2*1100delC carriers were women with BC, none of them had OC (Table 4) . Further, no other clinical or histological features investigated was influenced by the presence of this variant.
III-d. BRCA1 Mutations
Patients carrying a mutation in the BRCA1 gene were significantly younger when BC was diagnosed (p=0.002). When also BRCA1 UVs were considered, results did not change (p=0.028; results not shown).
III-e. BRCA2 Mutations
Patients carrying a mutation on the BRCA2 gene did not differ from patients being BRCA2 wild-type with respect to any of the clinical characteristics investigated.
IV. Gene-Gene Interactions
To evaluate the effect of co-occurrence of genetic risk factors we looked for patients having unfavorable clinical characteristics, such as occurrence of both BC and OC, BC twice, BC below the age of 40 years, or OC before the menopause and compared their frequency with the numbers of genetic risk alleles: none, one or two. The following combinations of genetic risk factors were investigated: +331A and BRCA1/2; PROGINS and BRCA1/2; +331A and PROG-INS; CHEK2*1100delC and +331A; and CHEK2*1100delC and PROGINS. Only the combination: +331A and BRCA1/2 resulted in significant differences in the distribution of patients having unfavourable features (p=0.02; Table 5 ). Notably, no patient carrying both +331A and a mutation in the BRCA1 or BRCA2 gene was seen in the average feature group, whereas all three patients carrying both +331A and a BRCA1 or BRCA2 mutation belonged to the group of patients with unfavorable clinical features. One of those women was +331A/A homozygous and carried a mutation in the BRCA2 gene, the other two women were +331G/A heterozygous and carried one BRCA1 mutation each. All those three women were diagnosed twice with BC.
DISCUSSION
Some case-control studies have suggested that PROGINS is protective against BC [2] but a risk-factor for OC [14, 15, 17] , whereas the +331A allele appeared to be a risk-factor both for BC [19] and for OC [15, 21] . Other authors, however, did not find any association [13, 17, [22] [23] [24] [25] [26] 28] . So far, the study of Runnebaum and coworkers [20] is the only one that investigates the effect of one of the PR polymorphisms (PROGINS) on BC and OC risk among BRCA1 and BRCA2 carriers and reports that PROGINS increases the risk for OC in BRCA1/2 mutation carriers who were never exposed to oral contraceptives.
In the present study, women carrying the PROGINS allele did not differ in the frequency of developing BC or OC compared to non-carriers. Interestingly, the PROGINS allele was significantly more frequent among men than among women diagnosed with BC. Breast cancer in men is a rare disease whose etiology is largely unknown [8] . Though, it appears that steroid hormone imbalances are important epidemiological risk-factors also in male BC and more than 90% of breast tumors in man are PR positive [29] . The number of male patients with BC in our study (n=6) was too small to draw any definitive conclusion, therefore, larger epidemiological studies are needed to confirm the role of PROGINS in male BC.
We observed a trend for an increased risk of OC and BC appearing twice among women carrying the +331A allele. The fact that those features were not significantly higher among BRCA1 and BRCA2 carriers may be due to insufficient statistical power, but may also reflect that +331A allele is a stronger predictor for both OC and multiple BC than BRCA1 and BRCA2.
We found evidence that suggest that the +331A allele in combination with BRCA1 or BRCA2 mutations have a synergistic effect. Firstly, the number of probands being homozygous +331A/A and carrying a mutation in the BRCA2 gene was significantly higher than in case they segregated independently. Interestingly the only two cases in this series who were homozygous +331A/A appeared to have either a mutation or a rare polymorphism in BRCA2. This additionally suggests that some rare polymorphisms are likely to be functional and to affect cancer risks. Secondly, a synergistic effect is further corroborated by the fact that all the patients carrying both +331A allele and a mutation in BRCA1 or BRCA2 belonged to the group with specially unfavorable clinical features, and had multiple BC events in particular. A molecular explanation of this synergistic effect for BR risk can be due to the fact that the +331A allele, as a result of the increased PRB/PRA expression increases cell proliferation in the breast epithelium (mediated by PRB) in response to progesterone [11, 12] . This, in combination with a defective DNA-repair machinery (due to a BRCA1 or BRCA2 variants), will facilitate the accumulation of cells with damaged DNA and, in turn, their malignant transformation.
CONCLUSION
In conclusion, we provide evidence that the PR +331A allele is a risk factor for familial BC/OC and acts as gene modifier in families with a BRCA1 or BRCA2 sequence variant. If independently confirmed by others, genetic screening of the +331G/A polymorphism should be considered together with BRCA1 and BRCA2 mutation detection for an individual risk assessment of the probands and their relatives. Whether PROGINS will result into a prevalent risk factor for male BC, should be assessed in series including a larger number of men with BC. 
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